KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Short-Term Debt issuances (2016 - 2025)

Eli Lilly's Short-Term Debt issuances history spans 16 years, with the latest figure at -$400000.0 for Q4 2025.

  • For Q4 2025, Short-Term Debt issuances fell 100.01% year-over-year to -$400000.0; the TTM value through Dec 2025 reached -$4.3 billion, down 134.23%, while the annual FY2025 figure was -$4.3 billion, 134.23% down from the prior year.
  • Short-Term Debt issuances reached -$400000.0 in Q4 2025 per LLY's latest filing, up from -$4.1 billion in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $4.6 billion in Q4 2023 to a low of -$5.2 billion in Q1 2024.
  • Average Short-Term Debt issuances over 5 years is -$11.8 million, with a median of -$2.5 million recorded in 2021.
  • Peak YoY movement for Short-Term Debt issuances: plummeted 9632.0% in 2022, then soared 1988.2% in 2023.
  • A 5-year view of Short-Term Debt issuances shows it stood at -$2.5 million in 2021, then tumbled by 9632.0% to -$243.3 million in 2022, then skyrocketed by 1988.2% to $4.6 billion in 2023, then plummeted by 33.78% to $3.0 billion in 2024, then tumbled by 100.01% to -$400000.0 in 2025.
  • Per Business Quant, the three most recent readings for LLY's Short-Term Debt issuances are -$400000.0 (Q4 2025), -$4.1 billion (Q3 2025), and $1.6 billion (Q2 2025).